![Mark Goldberg](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Goldberg
Directeur/Membre du Conseil chez
AVACTA GROUP PLC
Profil
Mark Alan Goldberg currently works at Avacta Group Plc, as Independent Non-Executive Director from 2021 and Walden Biosciences, Inc., as Director.
Dr. Goldberg also formerly worked at ImmunoGen, Inc., as Independent Director from 2011 to 2024, Idera Pharmaceuticals, Inc., as Independent Director from 2014 to 2022, aTyr Pharma, Inc., as Director from 2015 to 2017, American Cancer Society, Inc., as Director from 2019 to 2023, American Cancer Society, New England Division, Inc., as Director from 2010 to 2017, Blueprint Medicines Corp., as Independent Director from 2015 to 2025, Astellas Gene Therapies, Inc., as Independent Director from 2017 to 2020, Aceragen, Inc., as Director, GlycoMimetics, Inc., as Independent Director from 2014 to 2025, Genzyme Corp., as Senior Vice President-Clinical Research from 1996 to 2011, Dana-Farber Cancer Institute, Inc., as Principal, The Brigham & Women's Hospital, Inc., as Principal, Harvard Medical School, as Associate Professor from 1996 to 2018, Synageva BioPharma Corp., as Executive VP-Global Medical & Regulatory Strategy from 2011 to 2014, and CANbridge Life Sciences Ltd., as Chief Medical Officer from 2015 to 2018.
Dr. Goldberg received his doctorate degree from Harvard Medical School and undergraduate degree from Harvard College.
Postes actifs de Mark Goldberg
| Sociétés | Poste | Début |
|---|---|---|
| AVACTA GROUP PLC | Directeur/Membre du Conseil | 17/08/2021 |
Walden Biosciences, Inc.
 Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Provides renal therapeutics services | Directeur/Membre du Conseil | - |
Anciens postes connus de Mark Goldberg
| Sociétés | Poste | Fin |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Directeur/Membre du Conseil | 17/07/2025 |
GlycoMimetics, Inc.
 GlycoMimetics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat inflammatory diseases and cancer | Directeur/Membre du Conseil | 21/02/2025 |
| IMMUNOGEN, INC. | Directeur/Membre du Conseil | 12/02/2024 |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Directeur/Membre du Conseil | 28/09/2022 |
| AUDENTES THERAPEUTICS, INC. | Directeur/Membre du Conseil | 15/01/2020 |
Formation de Mark Goldberg
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
77
Relations au 1er degré
18
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 18 |
|---|---|
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology Develops anticancer therapeutics | Health Technology |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
aTyr Pharma, Inc.
 aTyr Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a bio therapeutics company that discovers and develops medicines based on novel biological pathways | Health Technology |
Dana-Farber Cancer Institute, Inc.
 Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Provides treatment to cancer patients | Health Services |
The Brigham & Women's Hospital, Inc.
 The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services Provides health care services | Health Services |
GlycoMimetics, Inc.
GlycoMimetics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat inflammatory diseases and cancer | Health Technology |
American Cancer Society, Inc.
 American Cancer Society, Inc. Miscellaneous Commercial ServicesCommercial Services Operates voluntary health organization for cancer research | Commercial Services |
Avacta Group Plc
 Avacta Group Plc Miscellaneous Commercial ServicesCommercial Services Engages in the business of healthcare technology and consumables | Commercial Services |
American Cancer Society, New England Division, Inc. | |
Harvard Medical School
 Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Blueprint Medicines Corp.
 Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Develops and manufactures biopharmaceutical products | Health Technology |
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Develops and commercializes gene therapy products for patients with serious rare diseases | Health Technology |
Harvard College
 Harvard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CANbridge Life Sciences Ltd.
 CANbridge Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Produces biopharmaceutical products | Health Technology |
Walden Biosciences, Inc.
Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Provides renal therapeutics services | Health Services |
Aceragen, Inc.
 Aceragen, Inc. BiotechnologyHealth Technology Discovers, develops, and commercializes therapeutics for oncology and rare diseases | Health Technology |
